Albemarle Corporation, a global leader in providing essential elements for mobility, energy, connectivity, and health, has generated net sales of $1.55 billion for the third quarter ended September 30, 2026, marking an 18.8% increase from the $1.31 billion recorded in Q3 2025.

The revenue growth was primarily propelled by a 68% pricing surge in the Energy Storage division, alongside a 10% price increase and a 3% volume improvement within the Specialties segment.

The company achieved a net income attributable to Albemarle of $296.8 million. This represents an outstanding recovery from the net loss of $160.7 million reported in the prior-year quarter. Furthermore, Adjusted EBITDA skyrocketed by 186% to $645.5 million, up from $225.6 million, supported heavily by ongoing corporate cost-efficiency and productivity initiatives.

Operationally, Albemarle highlighted significant progress at its production sites. In the Energy Storage unit, despite lower year-over-year sales volumes due to unusually high shipments in late 2025, the Greenbushes Talison Chemical Grade Plant 3 achieved a major milestone by maintaining 30 days of nameplate performance in September following earlier expansion delays. In the Specialties segment, market demand remained resilient across sectors like semiconductors and pharmaceuticals, further bolstered by record quarterly production at the Jordan Bromine Company joint venture.

Albemarle demonstrated excellent financial health, delivering $1.2 billion in year-to-date free cash flow and maintaining a strong operating cash conversion rate of 67%. As of September 30, 2026, the firm boasts total liquidity of approximately $3.4 billion, including $1.8 billion in cash and cash equivalents, against a manageable total debt of $1.9 billion.

Reflecting strict capital discipline, management optimized its full-year 2026 outlook. The company increased its full-year Specialties adjusted EBITDA guidance to between $350 million and $375 million. Concurrently, Albemarle reduced its full-year capital expenditure forecast to $300–$350 million through the resequencing of early-stage projects and optimized sourcing strategies.